About Aerovate Therapeutics, Inc. Common Stock
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Market Cap
$0.07B
Employees
51
Listed Since
June 30, 2021
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aerovatetx.comPhone
617-443-2400
Headquarters
930 WINTER STREET
WALTHAM, MA 02451
CIK
0001798749